Innoviva Specialty Therapeutics

Executive Summary

Innoviva Specialty Therapeutics is a private biotechnology company focused on developing and commercializing therapies for critical care and infectious diseases. With two approved products and a pipeline targeting drug-resistant infections, the company addresses high unmet medical needs in hospital and specialty settings. Its commercial portfolio generates revenue while it advances novel candidates for life-threatening conditions. The company's valuation of ~$1.7B reflects its potential in niche therapeutic areas. Although specific pipeline details are limited, Innoviva is positioned to leverage its expertise in anti-infectives and critical care to drive near-term growth. Key risks include reliance on a narrow product portfolio and competitive dynamics in infectious disease markets.

Upcoming Catalysts (preview)

• Q4 2026Potential label expansion for existing approved product60% success
• H1 2027Phase 2 data readout for a novel anti-infective candidate40% success
• Q3 2026Business development or licensing deal to expand pipeline50% success